Investor Overview

Corporate Profile

vTv Therapeutics LLC (vTv) is a clinical-stage pharmaceutical company focused on treating metabolic and inflammatory disorders to minimize their long-term complications and improve the lives of patients. Our mission is to advance clinical drug candidates discovered with our innovative technology into safe and effective medicines.

vTv has an innovative pipeline of first-in-class small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of metabolic and inflammatory disorders such as type 1 diabetes and psoriasis . The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality of vTv’s product candidate pipeline, scientific team, clinical trial execution and strategic collaborations have enabled it to become a leader in its novel therapeutic targets.

More >>

Recent News

Date Title
Toggle Summary vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021 , and provided an update on the progress of its clinical programs. “We plan to refocus vTv’s strategy on TTP399.  TTP399 is unique
Toggle Summary vTv Therapeutics Announces Deepa Prasad as New President and CEO
HIGH POINT, N.C. , Oct. 20, 2021 /PRNewswire/ --  vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that Deepa Prasad will lead the company as President and
Toggle Summary vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels Patients taking TTP399 reported no events of hypoglycemia, while four events of hypoglycemia were reported in the placebo arm Start-up activities for Phase 3 program ongoing with trials expected to begin in
Toggle Summary vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects Results build on data from previous multiple ascending dose study and support advancement of HPP737 into Phase 2 in moderate to severe psoriasis. Successful pre-IND meeting with U.S.
More >>
Upcoming Events
More events are coming soon.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.